5 Stocks Under $10 Setting Up to Trade Higher: Covisint and More
at The Street - Thu Dec 11, 11:46AM CST
Traders savvy enough to follow the low-priced names and trade them with discipline and sound risk management are banking ridiculous coin on a regular basis.
HRTX: 9.75 (+0.02), IO: 2.80 (+0.05), NXTD: 2.46 (-0.09), COVS: 2.73 (+0.08), SZMK: 6.12 (-0.07)
RedHill submits MAA for ondansetron
Seeking Alpha - at Seeking Alpha - Tue Dec 09, 11:38AM CST
INSY: 41.52 (+0.51), TSRO: 36.80 (+0.57), HRTX: 9.75 (+0.02), RDHL: 12.22 (-0.13), GWPH: 68.08 (+1.82), OPK: 9.63 (+0.21), GALE: 1.49 (-0.02)
Heron Therapeutics to Present at the Oppenheimer 25th Annual Healthcare Conference
Business Wire - Tue Dec 02, 7:01AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the Oppenheimer 25th Annual Healthcare Conference on Wednesday, December 10, 2014 at 2:10 p.m. ET in New York City.
HRTX: 9.75 (+0.02)
Heron Therapeutics beats 3Q profit forecasts
Automated Insights - Thu Nov 06, 9:07AM CST
REDWOOD CITY, Calif. (AP) _ Heron Therapeutics Inc. (HRTX) on Thursday reported a loss of $19.2 million in its third quarter.
HRTX: 9.75 (+0.02)
Heron Therapeutics Discloses New Proprietary Intravenous Formulation of NK-1 Receptor Antagonist for Prevention of CINV
Business Wire - Thu Nov 06, 7:10AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today disclosed a development program for a P/neurokinin-1 (NK1) receptor antagonist, which is used in the prevention of both acute- and delayed-onset chemotherapy induced nausea and vomiting (CINV). NK1 receptor antagonists are administered in combination with a 5-HT3 receptor antagonist for the prevention of CINV. Heron Therapeutics' lead investigational product candidate, SUSTOL(R) (granisetron injection, extended release), is an extended release 5-HT3 receptor antagonist being developed for the prevention of both acute- and delayed-onset CINV.
HRTX: 9.75 (+0.02)
Heron Therapeutics Announces Third Quarter and Year-to-Date 2014 Financial Results and Corporate Highlights
Business Wire - Thu Nov 06, 7:02AM CST
Heron Therapeutics, Inc. (NASDAQ:HRTX), a biotechnology company, today reported third quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
HRTX: 9.75 (+0.02)
Heron Therapeutics hires Esme C. Smith as VP
M2 - Tue Aug 26, 6:55AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) revealed on Monday the appointment of Esme C. Smith as its vice president, general counsel and secretary.
HRTX: 9.75 (+0.02)
Heron Therapeutics Appoints Esme C. Smith as Vice President, General Counsel and Secretary
Business Wire - Mon Aug 25, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today announced that Esme C. Smith will join the Company as Vice President, General Counsel and Secretary, effective today. Ms. Smith will report to Barry D. Quart, Pharm.D., Heron's Chief Executive Officer.
HRTX: 9.75 (+0.02)
Heron Therapeutics Announces Second Quarter and Year-to-Date 2014 Financial Results
Business Wire - Mon Aug 04, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress.
HRTX: 9.75 (+0.02)
4 Stocks Under $10 Making Big Moves
at The Street - Wed Jul 30, 5:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HRTX: 9.75 (+0.02), ACI: 1.78 (+0.01), CNAT: 6.84 (+0.17), IKGH: 1.25 (-0.09)
Heron Therapeutics closes public offering of common stock at USD11.75 per share
M2 - Tue Jul 01, 3:00AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) reported on Monday the completion of its public offering of 4,751,358 shares of common stock at USD11.75 per share.
HRTX: 9.75 (+0.02)
Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock
Business Wire - Mon Jun 30, 12:30PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced closing of its underwritten public offering of 4,751,358 shares of common stock at a public offering price of $11.75 per share. As a component of the offering, in lieu of common stock, Heron Therapeutics, Inc. also offered and sold to certain existing large investors pre-funded warrants to purchase up to an aggregate of 600,000 shares of common stock at a purchase price of $11.74 per warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. Gross offering proceeds to Heron Therapeutics, Inc. are approximately $63 million before deducting underwriting discounts and commissions and offering expenses payable by Heron Therapeutics, Inc.
HRTX: 9.75 (+0.02)
Heron Therapeutics (HRTX) in Focus: Stock Falls 8.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jun 26, 7:51AM CDT
Heron Therapeutics saw a big move last session on pretty good volume with far more shares changing hands than in a normal session; shares fell almost 9% on the day.
HRTX: 9.75 (+0.02), AERI: 29.49 (+1.23), ARIA: 6.81 (+0.15)
Why Heron Therapeutics Inc. Shares Tumbled
Sean Williams, The Motley Fool - Motley Fool - Wed Jun 25, 12:58PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Heron Therapeutics , a specialty...
HRTX: 9.75 (+0.02)
Heron Therapeutics, Inc. Announces Pricing of Underwritten Offering of Common Stock
Business Wire - Wed Jun 25, 8:15AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the pricing of an underwritten offering of 4,500,000 shares of its common stock, offered at a price of $11.75 per share. Heron Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. As a component of the offering, in lieu of common stock Heron Therapeutics, Inc. is offering to certain existing large investors pre-funded warrants to purchase up to an aggregate of 600,000 shares of common stock at a purchase price of $11.74 per warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each such pre-funded warrant. The offering is expected to close on or about June 30, 2014, subject to customary closing conditions. Jefferies LLC and Leerink Partners LLC are acting as joint book-runners for the offering. JMP Securities LLC, Brean Capital, LLC and Noble Financial Group, Inc. are acting as co-managers for the offering.
HRTX: 9.75 (+0.02)
Heron Therapeutics to issue common shares in planned underwritten offering
M2 - Wed Jun 25, 4:52AM CDT
Pharmaceutical company Heron Therapeutics (NasdaqCM:HRTX) said on Tuesday that it plans to offer and sell shares of its common stock in an underwritten offering.
HRTX: 9.75 (+0.02)
Heron Therapeutics, Inc. Announces Proposed Underwritten Offering of Common Stock
Business Wire - Tue Jun 24, 3:01PM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration. All of the shares in the proposed offering are to be sold by Heron Therapeutics, Inc.
HRTX: 9.75 (+0.02)
Heron Therapeutics (HRTX) in Focus: Stock Gains 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 8:25AM CDT
Heron Therapeutics (HRTX) was a big mover last session, with shares rising over 7% on the day.
HRTX: 9.75 (+0.02), AERI: 29.49 (+1.23), ARIA: 6.81 (+0.15)
Heron Therapeutics Set to Join Russell 3000 Index
Business Wire - Fri Jun 20, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, announced today that it is set to join the broad-market Russell 3000 Index, as well as the Russell Global and Russell Micro-Cap Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 27, 2014, according to a preliminary list of additions posted on June 13, 2014 on www.russell.com/indexes.
HRTX: 9.75 (+0.02)
Heron Therapeutics to Present at the 9th Annual JMP Securities Healthcare Conference
Business Wire - Thu Jun 12, 7:00AM CDT
Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, announced today that Barry D. Quart, Pharm.D., Chief Executive Officer of Heron Therapeutics, will present at the 9th Annual JMP Securities Healthcare Conference on Wednesday, June 25, 2014 at 3:00 p.m. ET in New York City.
HRTX: 9.75 (+0.02)